Premium
Mesenchymal stromal cell therapy for pancreatitis: Progress and challenges
Author(s) -
Ma Zhilong,
Zhou Jia,
Yang Tingsong,
Xie Wangcheng,
Song Guodong,
Song Zhenshun,
Chen Ji
Publication year - 2021
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21801
Subject(s) - mesenchymal stem cell , acute pancreatitis , pancreatitis , medicine , paracrine signalling , stromal cell , cell therapy , disease , cell , bioinformatics , cancer research , immunology , pathology , biology , receptor , genetics
Pancreatitis is a common gastrointestinal disease with no effective therapeutic options, particularly for cases of severe acute and chronic pancreatitis (CP). Mesenchymal stromal cells (MSCs) are multipotent cells with diverse biological properties, including directional migration, paracrine, immunosuppressive, and antiinflammatory effects, which are considered an ideal candidate cell type for repairing tissue damage caused by various pathogenies. Several researchers have reported significant therapeutic efficacy of MSCs in animal models of acute and CP. However, the specific underlying mechanisms are yet to be clarified and clinical application of MSCs as pancreatitis therapy has rarely been reported. This review mainly focuses on the potential and challenges in clinical application of MSCs for treatment of acute and CP, along with discussion of the underlying molecular mechanisms.